Rare disease biotech Electra picks commercially-minded Kathy Dong as next CEO
Electra Therapeutics is several years away from having a commercial product. And yet, the biotech’s new CEO Kathy Dong’s resume is stacked with experience on marketing and launching drugs—most notably, Gilead’s Sovaldi and Harvoni.
A Star is born as new SIRP player aims to Electra-fy rare disease
Star Therapeutics Inc. emerged from stealth mode to tell the world about its approach to drug discovery and development in rare diseases, and to spin out Electra Therapeutics Inc., the first in a projected family of companies. Deploying antibody drug discovery expertise, South San Francisco-based Star aims to generate programs that target multiple diseases with […]
Star’s Electra spinout turning SIRP proteins into depletion handles
The first in a series of spinouts from Star targeting biology shared by multiple diseases, Electra is leveraging insights into the SIRP protein family to stop pathogenic myeloid and T cell activity via a clinical-stage lead program, with a series of preclinical assets behind it. Electra Therapeutics Inc. and its parent company Star Therapeutics both emerged […]
Electra, one of 2 Star biotechs, snags $84M to apply brakes to ‘immune system haywire’
Electra Therapeutics, a member of the Star Therapeutics constellation, is going to be reaching for some of the 7,000 rare diseases, thanks to a new $84 million series B financing. The biotech, led by ex-True North Therapeutics executives, broke cover Wednesday with a monoclonal antibody in phase 1 trials in patients with the rare inflammatory […]
